Introduction
============

Cardiac fibrosis is characterized by the excessive proliferation of interstitial fibroblasts and excessive deposition of extracellular matrix. It is a common pathophysiologic mechanism during the development of various cardiovascular diseases such as atrial fibrillation, hypertensive heart disease, myocardial infarction and valvular heart diseases. Cardiac fibrosis has a key role in ventricular remodeling. The main pathological manifestations of cardiac fibrosis is myocardial stiffness increase, myocardial systolic and diastolic dysfunction, and eventually leading to heart failure and sudden death ([@b1-etm-0-0-7210],[@b2-etm-0-0-7210]). The current treatments available for cardiac fibrosis are not highly specific and often have many side effects. Therefore, a novel potential therapeutic agent for cardiac fibrosis is needed.

Acetazolamide is a carbonic anhydrase inhibitor, which is mainly applied for correct metabolic alkalosis ([@b3-etm-0-0-7210]) and edematous diseases such as COPD ([@b4-etm-0-0-7210]), cerebral edema ([@b5-etm-0-0-7210]) and chronic heart failure ([@b6-etm-0-0-7210]). Moreover, Li *et al* ([@b7-etm-0-0-7210]) also reported that acetazolamide could suppress tumor angiogenesis and metastasis in a Lewis lung carcinoma mouse model. Recently, Lin *et al* ([@b8-etm-0-0-7210]) reported that acetazolamide could enhance the cardioprotective effect of remifentanil in a rat model of myocardial ischemia/reperfusion injury. However, the effect of acetazolamide on cardiac fibrosis has not yet been confirmed. We hypothesized that acetazolamide may have potential usefulness in attenuating cardiac fibrosis. In this study, we created a mouse model of pressure overload induced by aortic constriction to investigate the effect of acetazolamide on cardiac fibrosis and the potential molecular mechanism.

Materials and methods
=====================

### Reagents

Acetazolamide was purchased from Sigma-Aldrich (Merck KGaA, Darmstadt, Germany). The rabbit anti-α-SMA, collagen I, TGF-β1 and Smad2 primary antibodies were purchased from Santa Cruz Biotechnology, Inc. (Dallas, TX, USA).

### Ethics statement

Male C57BL/6 mice (8--10 weeks old) were provided by the Animal Experiment Center of Affiliated Hospital of Jining Medical University (Jining, China). All aspects of the experimental protocols were approved by the Animal Care and Use Committee of Affiliated Hospital of Jining Medical University and conducted in accordance with the Guide for the Care and Use of Laboratory Animals, published by the US National Institutes of Health (NIH Publication no. 85-23, revised 1996). The mice were housed in a temperature controlled room (21±2°C) with a relative humidity range of 30 to 40% on a 12:12-h light/dark cycle (lights on at 06:00). All rats had free access to water and food.

### Animal model of pressure overload

The mice were anesthetized with an initial 4% isoflurane followed by a maintenance dose of 2% isoflurane, then intubated and ventilated. A midline incision was made at the sternum. After opening the mediastinal space, the aortic arch was blunt dissected at the base of the heart. A blunt 27-G injection needle (OD 0.4 mm) was placed parallel to the aorta between the left carotid and the right innominate arteries, then the needle and the aortic arch were tied together using a 7-0 suture. After removing the needle, a model of aortic constriction was created. Sham mice underwent the same surgical procedure, the 7-0 suture was placed in the same position without ligation. After transverse aortic constriction (TAC) or sham operation, the mice were orally gavaged with acetazolamide (20 mg/kg/day). There are four groups in this experiment: i) sham group; ii) sham+acetazolamide group; iii) TAC group; iv) TAC + ace-tazolamide group, n=10 mice in each group. After 4 weeks of operation, all mice were sacrificed and the hearts were harvested. The heart samples were frozen in liquid nitrogen frozen and then stored at −70°C.

### Echocardiography

After 4 weeks of operation, the mice were anesthetized by isoflurane and the cardiac function was detected using a rodent animal ultrasonic instrument (Vevo 2100; VisualSonics, Inc., Toronto, ON, Canada). The interventricular septum diameter (IVS), left ventricular (LV) posterior wall thickness (LVPW) and LV ejection fraction (LVEF) were calculated.

### Western blotting

Total proteins were isolated from heart tissues using a protein extraction kit (Nanjing KeyGen Biotech Co., Ltd., Nanjing, China). Total protein concentration was calculated by bicinchoninic acid (BCA) Protein Assay Kit (Pierce, Rockford, IL, USA). Gel electrophoresis (10%) was performed to separate the different molecular weight proteins and then transferred onto polyvinylidene difluoride membranes. A total of 30 µg proteins were added into per lane for the electrophoresis. Bull Serum Albumin (BSA) Blocking buffer (5%) was used as the blocking reagent. The membrane was incubated with α-SMA, collagen I, TGF-β1, phospho-Smad2 and Smad2 for overnight at 4°C. After incubation with the primary antibodies, the membrane was washed in Tris-buffered saline-tween (TBST) and then incubated with the HRP-conjugated secondary antibody at room temperature for another 2 h. Rabbit polyclonal α-SMA antibody (dilution, 1:1,000; cat. no. ab5694); rabbit monoclonal collagen I antibody (dilution, 1:1,000; cat. no. ab138492); rabbit monoclonal TGF-β1 antibody (dilution, 1:1,000; cat. no. ab215715); rabbit monoclonal phospho-Smad2 antibody (dilution, 1:1,000; cat. no. ab188334); rabbit monoclonal Smad2 antibody (dilution, 1:1,000; cat. no. ab40855); rabbit polyclonal GAPDH antibody (dilution, 1:1,000; cat. no. ab37168) and secondary goat anti-rabbit (HRP) IgG antibody (dilution, 1:2,000; cat. no. ab6721) were all purchased from Abcam (Cambridge, MA, USA). Immuno-reactive bands were visualized by enhanced chemiluminescence (ECL) detection kit (Amersham Biosciences, Foster City, CA, USA). ImageJ software (NIH, Bethesda, MD, USA) was used to measure the blot signal and density.

### Histological assessment of cardiac fibrosis

The LV tissue samples were fixed in paraformaldehyde (3.7% in phosphate-buffered saline (PBS), freshly prepared) for 24 h and then embedded in paraffin. LV sections (4--5 µm) were stained with Masson\'s trichrome for interstitial fibrosis. The proportion of the total fibrosis area was observed using a microscope (Nikon, Tokyo, Japan) and was calculated by ImageJ software (NIH), as the blue-stained areas divided by the total LV area.

### Statistical analysis

SPSS 19.0 software (IBM Corp., Armonk, NY, USA) was used for statistical analysis. All results were presented as means ± standard deviation (means ± SD). One-way ANOVA followed by post hoc test (Least Significant Difference) was used to compare the differences among the different groups. Student\'s t-test was used to compare the differences between the two groups. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Acetazolamide attenuates cardiac dysfunction and interstitial fibrosis induced by TAC

As shown in [Fig. 1](#f1-etm-0-0-7210){ref-type="fig"}, the interventricular septum diastolic dimension (IVSD) and LV posterior wall thickness diastole (LVPWD) were significantly thicker in the TAC mice than those in the sham mice (P\<0.01, P\<0.01, respectively). Moreover, the LVEF was significantly decreased in the TAC mice compared with the sham mice (P\<0.001). By contrast, acetazolamide administration significantly decreased the IVSD and LVPWD, and inhibited the reduction in LVEF induced by TAC (P\<0.01, P\<0.05, P\<0.01, respectively).

As shown in [Fig. 2](#f2-etm-0-0-7210){ref-type="fig"}, the interstitial collagen volume was substantially increased in the TAC group compared with the sham group (P\<0.01). By contrast, acetazolamide administration significantly inhibited TAC-induced interstitial fibrosis (P\<0.05).

### Acetazolamide inhibits the TAC-induced increase in the expression of α-SMA and collagen I proteins

As shown in [Fig. 3](#f3-etm-0-0-7210){ref-type="fig"}, the expression of α-SMA and collagen I proteins were significantly increased in TAC group compared with the sham group (P\<0.001, P\<0.001, respectively). Acetazolamide administration reduced the expression of α-SMA and collagen I proteins in contrast to the TAC group (P\<0.01, P\<0.01, respectively).

### Acetazolamide inhibits the activation of TGF-β1/Smad2 signaling pathway

As shown in [Fig. 4](#f4-etm-0-0-7210){ref-type="fig"}, the expression of TGF-β1 and phosphorylation level of Smad2 were significantly increased in TAC group compared with the sham group (P\<0.01, P\<0.001, respectively). Acetazolamide administration reduced the expression of TGF-β1 and phosphorylation level of Smad2 in contrast to the TAC group (P\<0.01, P\<0.01, respectively).

Discussion
==========

To the best of our knowledge, the present study provides the first report that acetazolamide is able to inhibit cardiac fibrosis and dysfunction induced by pressure overload in mice. The anti-fibrotic effect of acetazolamide was confirmed by the reduction of collagen volume in myocardial interstitium and the inhibition of α-SMA and collagen I protein expression. Acetazolamide also inhibited the activation of TGF-β1/Smad2 signaling pathway. These findings support the conclusion that acetazolamide possibly is a potential therapeutic agent for the prevention of cardiac fibrosis.

Cardiac fibrosis is an important hallmark during the development of ventricular remodeling, and is a key pathological foundation of cardiac dysfunction and malignant cardiovascular events ([@b2-etm-0-0-7210]). The development of cardiac fibrosis is associated with the activation of renin angiotensin-aldosterone system, oxidative stress and a variety of cytokines. TGF-β1 is a cytokine that performed a variety of biological functions including promoting cell proliferation and differentiation, promoting collagen synthesis, and inhibiting collagen degradation. It has been demonstrated that TGF-β1 is one of the most important factors for inducing cardiac fibrosis ([@b9-etm-0-0-7210]). During the development of cardiac fibrosis, activated TGF-β1 can promote cardiac fibroblast differentiation into myofibroblasts, as reflected by the expression of α-SMA ([@b10-etm-0-0-7210]). Rosenkranz *et al* ([@b11-etm-0-0-7210]) reported that the overexpression of TGF-β1 could induce cardiac fibrosis and hypertrophy in transgenic mice. Furthermore, in a rat model of pressure-overload, Kuwahara *et al* ([@b12-etm-0-0-7210]) found that TGF-β1 function blocking could inhibit cardiac fibrosis and dysfunction. Collagen I is secreted by myofibroblasts and is the most abundant collagen type in the myocardium, constituting \~80% of the extracellular matrix ([@b1-etm-0-0-7210]). The overexpression of collagen I in transgenic mice displayed significant cardiac fibrosis and dysfunction ([@b13-etm-0-0-7210]). Similarly, in this study, we created a pressure overload model to induce cardiac fibrosis. Our results showed that the mice displayed significant cardiac fibrosis after 4 weeks of TAC, as confirmed by Masson staining and increased collagen volume. The expression of TGF-β1, α-SMA and collagen I proteins was also markedly increased in the pressure-overloaded myocardium. Acetazolamide administration significantly attenuated cardiac fibrosis and inhibited the expression of TGF-β1, α-SMA and collagen I in the pressure-overloaded myocardium.

TGF-β1/Smad signaling is the main pathway during the development of cardiac fibrosis ([@b9-etm-0-0-7210],[@b14-etm-0-0-7210]). The protein Smads are the key downstream signaling molecules triggered by TGF-β1 and then induce the expression of pro-fibrotic target genes ([@b9-etm-0-0-7210]). Lei *et al* ([@b15-etm-0-0-7210]) reported that Smad2 siRNA could significantly inhibit TGF-β1-induced fibrotic changes in rat cardiac fibroblasts. Huang *et al* ([@b16-etm-0-0-7210]) also found that Smad3 activation could induce cardiac fibrosis in a myocardial remodeling model. Conversely, Smad7 activation could inhibit cardiac fibrosis and dysfunction induced by angiotensin II ([@b17-etm-0-0-7210]). Similarly, in this study, we found that the phosphorylation level of Smad2 was significantly increased in the TAC mice. Acetazolamide administration reduced the phosphorylation level of Smad2 in the pressure-overloaded myocardium. Our results demonstrated that acetazolamide significantly attenuated cardiac fibrosis and dysfunction induced by pressure overload through inhibiting the TGF-β1/Smad2 signaling pathway.

In conclusion, this is the first study to identify that acetazolamide inhibit the development of cardiac fibrosis. The molecular mechanism involved in the anti-fibrotic effect of acetazolamide was possibly through inhibiting TGF-β1/Smad2 signaling pathway. Our results suggest that acetazolamide may be used as a therapeutic agent for the prevention of cardiac fibrosis. Further research is needed to investigate the effect and mechanism of acetazolamide in cardiac fibroblasts *in vitro*.
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